Ganoderma lucidum in Non alcoholic fatty liver disease patient

Phase 2

• Conditions: Condition 1: Non alcoholic fatty liver disease. Condition 2: Fatty liver disease.; Non-alcoholic fatty liver disease; Non-alcoholic fatty liver disease, unspecified; DB92; DB92.Z

• Registration Number: IRCT20191217045763N1
• Lead Sponsor: Semnan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patient refered to gastroentrology clinic of semnan kosar hospital
Diagnose is Non alcoholic fatty liver disease
Don't receive treatment yet

Exclusion Criteria

No sonographic change for fatty liver
Alcoholic fatty liver
Other liver disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effects of Ganoderma lucidum on ALT in Non alcoholic fatty liver disease patient. Timepoint: 12 week. Method of measurement: Laboratory Reference.;Effects of Ganoderma lucidum on AST in Non alcoholic fatty liver disease patient. Timepoint: 12 week. Method of measurement: laboratory Reference.

Secondary Outcome Measures

Name	Time	Method
CHOLESTROL. Timepoint: 12 week. Method of measurement: Laboratory reference.;LDL. Timepoint: 12week. Method of measurement: Laboratory reference.;HDL. Timepoint: 12 week. Method of measurement: Laboratory reference.